Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ceftazidime pentahydrate
Drug ID BADD_D00400
Description Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs).[A232920] β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death.[A232920, A232925, A232930] Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as _Pseudomonas aeruginosa_.[L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of bacterial infections.[L32935, L32940]
Indications and Usage For the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis).
Marketing Status Prescription; Discontinued
ATC Code J01DD02
DrugBank ID DB00438
KEGG ID D00921
MeSH ID D002442
PubChem ID 5362051
TTD Drug ID D0PH5Z
NDC Product Code 25021-129; 44567-237; 52946-0924; 0264-3145; 44567-235; 0264-3143; 25021-128; 25021-127; 0409-5084; 0409-5086; 10402-013; 44567-236; 0409-5092; 0409-5082; 0409-5093
Synonyms Ceftazidime | Fortaz | Fortum | Ceftazidime Pentahydrate | LY-139381 | LY 139381 | LY139381 | Tazidime | Ceftazidime Anhydrous | Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))- | GR-20263 | GR 20263 | GR20263
Chemical Information
Molecular Formula C22H32N6O12S2
CAS Registry Number 78439-06-2
SMILES CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O -].O.O.O.O.O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemolytic anaemia01.06.03.002--Not Available
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001--Not Available
Hyperbilirubinaemia14.11.01.010; 09.01.01.003; 01.06.04.003--Not Available
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Instillation site pain12.07.01.008; 08.02.01.008--Not Available
Jaundice01.06.04.004; 23.03.03.030; 09.01.01.004--Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.003--
Leukopenia01.02.02.001--Not Available
Local reaction08.01.03.012--Not Available
Lymphocytosis01.02.01.003--Not Available
Myoclonus17.02.05.008--Not Available
Nausea07.01.07.001--
Nephropathy20.05.03.001--Not Available
Nephropathy toxic20.05.03.002; 12.03.01.010--Not Available
Neutropenia01.02.03.004--Not Available
Oral candidiasis11.03.03.004; 07.05.07.001--Not Available
Pancytopenia01.03.03.003--Not Available
Paraesthesia17.02.06.005--
Phlebitis24.05.03.001; 12.02.01.002--
Prothrombin level increased13.01.02.011--Not Available
Prothrombin time prolonged13.01.02.012--Not Available
Pruritus23.03.12.001--
Pseudomembranous colitis11.02.02.002; 07.19.01.003--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages